{
  "Variants Include": [
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_198578.4:c.5095T>G",
          "cDNA Change": {
            "transcript": "NM_198578.4",
            "ref": "T",
            "alt": "G",
            "position": "5095"
          },
          "Protein Change": {
            "ref": "Y",
            "alt": "C",
            "position": "1699"
          },
          "Description in input context": "Y1699C"
        },
        {
          "HGVS": "NM_198578.4:c.6055G>A",
          "cDNA Change": {
            "transcript": "NM_198578.4",
            "ref": "G",
            "alt": "A",
            "position": "6055"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005180"
  },
  "Experiment Method": [
    {
      "Assay Method": "Cell Viability Assay (WST-1)",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293",
        "Description": "Cell viability of HEK293 cells was determined using the WST-1 assay kit (Roche, Penzberg, Germany) in accordance with the manufacturer's recommended protocol."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_198578.4:c.5095T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "N.D.",
          "Result Description": "Expression of LRRK2 wild-type, Y1699C and G2019S genes in HEK293 cells resulted in a consistent 30–45% drop in basal viability with no significant difference between them."
        },
        {
          "Variant": "NM_198578.4:c.6055G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "N.D.",
          "Result Description": "Expression of LRRK2 wild-type, Y1699C and G2019S genes in HEK293 cells resulted in a consistent 30–45% drop in basal viability with no significant difference between them."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "All values in the figures were calculated from at least 2-3 independent experiments with each experiment containing at least 6–8 replicates in each experimental condition."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Results are reported as mean value ± SEM. The significance of difference between means was assessed by ANOVA and post hoc Fisher's protected least significant difference (PLSD) tests, with p<0.05 considered statistically significant."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Decrease by 30-45%.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "LDH Assay",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293",
        "Description": "LDH release was measured in the present study to quantify necrotic cell death induced by MPP+ using the LDH assay kit developed by Pointe Scientific, Inc. (Fisher Scientific, Pittsburgh, PA, USA)."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_198578.4:c.5095T>G",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "Chronic treatment with 150µM of H2O2 resulted in 10% of necrotic cell death, indicating that the predominant mode of cell death at these conditions is apoptosis."
        },
        {
          "Variant": "NM_198578.4:c.6055G>A",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "Chronic treatment with 150µM of H2O2 resulted in 10% of necrotic cell death, indicating that the predominant mode of cell death at these conditions is apoptosis."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "All values in the figures were calculated from at least 2-3 independent experiments with each experiment containing at least 6–8 replicates in each experimental condition."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Results are reported as mean value ± SEM. The significance of difference between means was assessed by ANOVA and post hoc Fisher's protected least significant difference (PLSD) tests, with p<0.05 considered statistically significant."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Necrotic cell death over 10%.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Cell Count (Hoechst stain)",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "SH-SY5Y",
        "Description": "Cell density of SH-SY5Ycells expressing LRRK2 wild-type, Y1699C or G2019S mutant were determined by direct cell count due to the presence of GFP fusion to each of the genes."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_198578.4:c.5095T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "N.D.",
          "Result Description": "A decrease in basal viability of 20% in cells expressing Y1699C and nearly 30% in cells G2019S than those cells expressing LRRK2 wild-type."
        },
        {
          "Variant": "NM_198578.4:c.6055G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "N.D.",
          "Result Description": "A decrease in basal viability of 20% in cells expressing Y1699C and nearly 30% in cells G2019S than those cells expressing LRRK2 wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "For each treatment conditions, three independent frames of the cells were captured showing cells expressing LRRK2-GFP fusion. The same frames of the cells stained with Hoechst stain to reveal total number of cells was captured too."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Results are reported as mean value ± SEM. The significance of difference between means was assessed by ANOVA and post hoc Fisher's protected least significant difference (PLSD) tests, with p<0.05 considered statistically significant."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Decrease by over 20% in cell viability.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293",
        "Description": "Standard PAGE and Western blotting protocols recommended by Cell Signaling Technology (Danvers, MA, USA) were used in this study."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_198578.4:c.5095T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "N.D.",
          "Result Description": "The basal level of pERK was decreased in cells expressing wild-type LRRK2 and Y1699C mutant with no change to the level of total ERK1/2 (tERK). Moreover, the decrease in the basal level of pERK in cells expressing Y1699C mutant was higher in cells expressing wild-type LRRK2. In contrast, there was no significant change in the basal level of pJNK or total JNK (tJNK) in cells expressing wild-type LRRK2 and Y1699C mutant to those transfected with pCDNA3.1. On the other hand, after 18 hours of treatment with H2O2 at EC50 (150µM), cells expressing wild-type LRRK2 consistently elicited a higher level of pERK than those expressing Y1699C mutant with no significant change in the level of tERK. As to pJNK and tJNK, there was no significant difference in their level changes in response H2O2 toxicity between cells expressing wild-type LRRK2 and Y1699C mutant."
        },
        {
          "Variant": "NM_198578.4:c.6055G>A",
          "Conclusion": "N.D.",
          "Molecular Effect": "N.D.",
          "Result Description": "The basal level of pERK was decreased in cells expressing wild-type LRRK2 and Y1699C mutant with no change to the level of total ERK1/2 (tERK). Moreover, the decrease in the basal level of pERK in cells expressing Y1699C mutant was higher in cells expressing wild-type LRRK2. In contrast, there was no significant change in the basal level of pJNK or total JNK (tJNK) in cells expressing wild-type LRRK2 and Y1699C mutant to those transfected with pCDNA3.1. On the other hand, after 18 hours of treatment with H2O2 at EC50 (150µM), cells expressing wild-type LRRK2 consistently elicited a higher level of pERK than those expressing Y1699C mutant with no significant change in the level of tERK. As to pJNK and tJNK, there was no significant difference in their level changes in response H2O2 toxicity between cells expressing wild-type LRRK2 and Y1699C mutant."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "N.D.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Lower level of pERK.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}